Narender Jogenpally, MD
Hematology & Oncology · South Charleston, WVNPI 1396741880
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.6% of the total across 37 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $311 and has fallen 95.4% since, to $14 in 2025. That places this record below the midpoint for hematology & oncology clinicians in WV, where the typical reported total is $1,186.
Across 37 payments — averaging $23.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$132
- Novartis$126
- Johnson & Johnson$103
- Rigel Pharmaceuticals, Inc.$94
- Astellas Pharma US Inc$54
- E.r. Squibb & Sons, L.L.C.$47
- plus $301 from 12 others
What the payments were for
- Food & beverage$80194%
- Education$556%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 2 | $132 |
| Novartis | 7 | $126 |
| Johnson & Johnson | 5 | $103 |
| Rigel Pharmaceuticals, Inc. | 1 | $94 |
| Astellas Pharma US Inc | 3 | $54 |
| E.r. Squibb & Sons, L.L.C. | 3 | $47 |
| Tesaro, Inc. | 2 | $38 |
| GSK | 2 | $37 |
| Bristol Myers Squibb | 2 | $35 |
| Pfizer | 2 | $33 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Seagen Inc. | 1 | $24 |
| Amgen | 1 | $23 |
| Beigene USA, Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Merck | 1 | $19 |
| Medtronic | 1 | $14 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$111
How this compares
$856 in reported general payments places this provider in the 45th percentile of 72 hematology & oncology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 69 | $1,085,053 |
| TasignaNilotinib Hcl | 40 | $706,464 |
| JakafiRuxolitinib Phosphate | 37 | $623,126 |
| PomalystPomalidomide | 29 | $545,263 |
| Lenalidomide | 43 | $491,160 |
| CalquenceAcalabrutinib Maleate | 29 | $423,668 |
| Abiraterone Acetate | 112 | $385,980 |
| PromactaEltrombopag Olamine | 36 | $385,231 |
| InlytaAxitinib | 22 | $321,330 |
| ImbruvicaIbrutinib | 22 | $285,240 |
| SprycelDasatinib | 12 | $205,819 |
| LynparzaOlaparib | 12 | $187,811 |
| MekinistTrametinib Dimethyl Sulfoxide | 12 | $172,833 |
| TafinlarDabrafenib Mesylate | 11 | $146,716 |
| VenclextaVenetoclax | 13 | $118,841 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisTasigna, Promacta, Mekinist, Tafinlar | $126 | $1,411,24399 claims |
| PfizerIbrance, Inlyta | $33 | $1,406,38391 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $47 | $751,08241 claims |
| AstraZenecaCalquence, Lynparza | $132 | $611,47941 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 72 hematology & oncology providers in West Virginia.
Other hematology & oncology in South Charleston
- John PonugupatiSouth Charleston$3K
- Damian SilberminsHuntington$277K
- Abraham KanateMorgantown$169K
- Salman OsmanBridgeport$118K
- Ashkan EmadiMorgantown$88K
- Konstantinos SdrimasMorgantown$81K
- Arvinder BirHuntington$74K
- Bhavana BhatnagarWheeling$72K
- Ihtishaam QaziMorgantown$18K
- Matias ValsecchiHuntington$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.